Barclays’s GoodRx Holdings GDRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$391K Sell
199,555
-112,910
-36% -$265K ﹤0.01% 3329
2025
Q4
$847K Sell
312,465
-5
-0% -$16 ﹤0.01% 3555
2025
Q3
$1.32M Buy
312,470
+172,216
+123% +$757K ﹤0.01% 3198
2025
Q2
$698K Buy
140,254
+164
+0.1% +$712 ﹤0.01% 3567
2025
Q1
$618K Sell
140,090
-25,838
-16% -$121K ﹤0.01% 3392
2024
Q4
$772K Buy
165,928
+25,815
+18% +$142K ﹤0.01% 3550
2024
Q3
$972K Buy
140,113
+130,219
+1,316% +$1.02M ﹤0.01% 3380
2024
Q2
$77.2K Sell
9,894
-19,500
-66% -$144K ﹤0.01% 4030
2024
Q1
$209K Buy
29,394
+9,483
+48% +$62.7K ﹤0.01% 4096
2023
Q4
$133K Buy
19,911
+1,051
+6% +$5.92K ﹤0.01% 4557
2023
Q3
$106K Buy
18,860
+351
+2% +$2.34K ﹤0.01% 3583
2023
Q2
$102K Buy
18,509
+12,722
+220% +$68.5K ﹤0.01% 3551
2023
Q1
$36.2K Hold
5,787
﹤0.01% 4517
2022
Q4
$27K Buy
5,787
+216
+4% +$1.06K ﹤0.01% 4749
2022
Q3
$26K Sell
5,571
-36,612
-87% -$231K ﹤0.01% 3976
2022
Q2
$250K Buy
42,183
+17,322
+70% +$193K ﹤0.01% 3317
2022
Q1
$480K Buy
+24,861
New +$570K ﹤0.01% 2940

Other funds holding GDRX

Barclays's GDRX Position: Q1 2026 in Review

Barclays reduced its GoodRx Holdings (GDRX) stake by 36% in Q1 2026, selling an estimated $265K and leaving 199,555 shares worth $391K. The position accounts for ﹤0.01% of the portfolio, ranked #3329.

Barclays first reported a position in GDRX in Q1 2022 and has held it in 17 quarters since. The position peaked at $1.32M in Q3 2025. 174 funds tracked by Wall St. Rank hold GDRX as of Q1 2026.

  • Barclays held 199,555 shares of GoodRx Holdings worth $391K as of Q1 2026.
  • Barclays sold 112,910 GoodRx Holdings shares in Q1 2026, an estimated $265K.
  • GoodRx Holdings made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3329 holding.
  • Barclays first reported a position in GoodRx Holdings in Q1 2022 and has held it in 17 quarters since.
  • Barclays's GoodRx Holdings position peaked at $1.32M in Q3 2025.
  • 174 funds tracked by Wall St. Rank held GoodRx Holdings as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.